These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Risk of intracranial haemorrhage in patients with atrial fibrillation treated with novel oral anticoagulants: testing the equivalence margins between dabigratran, rivaroxaban and apixaban. Messori A; Maratea D; Fadda V; Trippoli S Eur J Clin Pharmacol; 2014 Apr; 70(4):505-6. PubMed ID: 24452835 [No Abstract] [Full Text] [Related]
7. Increasing Use of Anticoagulants in Germany and Its Impact on Hospitalization for Intracranial Bleeding. Gülker JE; Kröger K; Kowall B; Dingelstadt M; Stang A Circ Cardiovasc Qual Outcomes; 2018 May; 11(5):e004470. PubMed ID: 29748354 [No Abstract] [Full Text] [Related]
9. Variability in the benefit of the novel oral anticoagulant agents in patients with non-valvular atrial fibrillation. Patti G; Cavallari I Intern Emerg Med; 2015 Apr; 10(3):395-6. PubMed ID: 25487959 [No Abstract] [Full Text] [Related]
10. New Oral Anticoagulants (NOAC) Studies in the Ideal and the Real World - Needs of Prospective Observational Studies. Kokubo Y Circ J; 2015; 79(5):962-3. PubMed ID: 25865151 [No Abstract] [Full Text] [Related]
11. New oral anticoagulants and the risk of intracranial hemorrhage: traditional and Bayesian meta-analysis and mixed treatment comparison of randomized trials of new oral anticoagulants in atrial fibrillation. Chatterjee S; Sardar P; Biondi-Zoccai G; Kumbhani DJ JAMA Neurol; 2013 Dec; 70(12):1486-90. PubMed ID: 24166666 [TBL] [Abstract][Full Text] [Related]
12. Establishing comparable requirements and treatment groups before applying statistical comparison. Stöllberger C; Finsterer J JAMA Neurol; 2014 Mar; 71(3):369-70. PubMed ID: 24614991 [No Abstract] [Full Text] [Related]
13. [Anticoagulation for atrial fibrillation in the patient at risk for falls]. Petreska I; Perrier A Rev Med Suisse; 2015 Oct; 11(490):1899-900, 1902-3. PubMed ID: 26665659 [TBL] [Abstract][Full Text] [Related]
14. Establishing comparable requirements and treatment groups before applying statistical comparison-reply. Chatterjee S; Sardar P; Biondi-Zoccai G; Kumbhani DJ JAMA Neurol; 2014 Mar; 71(3):371-2. PubMed ID: 24614993 [No Abstract] [Full Text] [Related]
15. [Programs for Continuing Medical Education: B session; 2. Non-vitamin K antagonist oral anticoagulants for atrial fibrillation]. Yamashita T Nihon Naika Gakkai Zasshi; 2015 Mar; 104(3):540-5. PubMed ID: 26571739 [No Abstract] [Full Text] [Related]
16. Fall risk and anticoagulation for atrial fibrillation in the elderly: A delicate balance. Hagerty T; Rich MW Cleve Clin J Med; 2017 Jan; 84(1):35-40. PubMed ID: 28084982 [TBL] [Abstract][Full Text] [Related]
17. To Treat or Not to Treat: Anticoagulants as Secondary Preventives to the Oldest Old With Atrial Fibrillation. Appelros P; Farahmand B; Terént A; Åsberg S Stroke; 2017 Jun; 48(6):1617-1623. PubMed ID: 28487335 [TBL] [Abstract][Full Text] [Related]
18. Intracranial bleedings in patients on long-term anticoagulant treatment: Benefits from oral thrombin and factor Xa inhibitors in clinical practice. Łukasik M; Zawilska K; Undas A Neurol Neurochir Pol; 2015; 49(3):171-9. PubMed ID: 26048605 [TBL] [Abstract][Full Text] [Related]
19. Response to letter regarding article, "Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control". Chan PH; Hai JJ; Siu CW Stroke; 2015 Mar; 46(3):e72. PubMed ID: 25649808 [No Abstract] [Full Text] [Related]
20. Effect of Anticoagulation on Hospitalization Costs After Intracranial Hemorrhage in Atrial Fibrillation: A Registry Study. Vestergaard AS; Skjøth F; Lip GY; Larsen TB Stroke; 2016 Apr; 47(4):979-85. PubMed ID: 26883499 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]